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Resumo 
 Demonstrámos recentemente, que uma dose única e elevada de 
metanfetamina (METH) causou um fenótipo depressivo de longa duração, aferido pelo 
aumento do tempo de imobilidade no teste de tail suspension. Tem sido demonstrado que o 
exercício físico alivia os sintomas depressivos. 
Propomo-nos confirmar e caracterizar mais detalhadamente o fenótipo depressivo 
causado por uma única injecção neurotóxica de METH e investigar a correlação entre a 
homeostase de 5-HT no córtex frontal e hipocampo e o efeito antidepressivo de exercício 
físico. 
Murganhos adultos C57BL/6 foram submetidos a um programa de exercício em 
treadmill (cinco dias por semana durante sete semanas) a partir de 24 h após uma única 
dose elevada de METH (30 mg/kg, i.p.), tendo sido organizados da seguinte forma 
(n=8/grupo): salino/sedentário; METH/sedentário; salino/exercício e METH/exercício. Em 
seguida, avaliou-se a exploração/actividade locomotora, anedonia e desespero 
(comportamentos do tipo depressivo) numa fase tardia da privação de METH (49 dias) 
através dos testes open-field, splash e forced-swim, respectivamente. Os teores totais de 5-
HT no cortex-frontal e hipocampo (49 dias pós-METH) foram avaliados por cromatografia 
líquida de fase reversa e de alta eficiência (HPLC). Avaliámos o impacto inicial (3 dias 
pós-METH) de METH nos níveis totais de 5-HT do hipocampo noutro grupo de 
murganhos (16). 
É importante registar que a METH diminuiu o tempo de grooming dos murganhos 
sedentários, no teste splash. Isto demonstra que esta dose de METH induz um 
comportamento do tipo anedónico. Por outro lado, confirmou-se ainda que a METH induz 
um comportamento do tipo depressivo de longa duração. Além disso, o exercício em 
treadmill reverteu o tempo de grooming no teste splash, 7 semanas após a injecção de 
METH. Este efeito antidepressivo foi ainda aferido por uma diminuição do tempo de 
imobilidade e um aumento do tempo de natação no teste forced-swim exibido pelos 
murganhos, control ou submetidos à METH. Adicionalmente, o exercício aumentou a 
actividade locomotora, o comportamento exploratório e a razão distância central - distância 
total nos murganhos control ou submetidos à METH no teste open-field. Isto é consistente 
com o facto de o exercício físico induzir um estado de bem-estar emocional, 
independentemente do tratamento farmacológico. Por outro lado, a METH não alterou 
significativamente os parâmetros motores de murganhos sedentários. Isto é relevante, visto 
 ix 
 
que sugere que a actividade locomotora não contribuiu para o comportamento do tipo 
anedónico observado.  
A análise neuroquímica mostrou que a METH provocou uma deplecção robusta de 
5-HT no hipocampo nos primeiros 3 dias após a injecção de METH, que foi recuperada 49 
dias após o tratamento. Além disso, o exercício físico não teve um impacto significativo 
nos níves hipocampais de 5-HT. Adicionalmente, nem o exercício físico nem a METH 
alteraram significativamente os teores toatis de 5-HT. 
É importante destacar, que demostrámos que um programa de sete semanas de 
exercício em treadmill promoveu um efeito antidepressivo em murganhos intoxicados com 
METH. No entanto, este benefício do exercício não está associado a altenações na 
homeostase serotonérgica fronto-cortical/hipocampal. 
 
 
Palavras-chave: metanfetamina, neurotoxicidade, depressão, serotonina, exercício 
físico, córtex frontal, hipocampo, murganho. 
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Abstract 
Recently we demonstrated that a single high neurotoxic dose of methamphetamine 
(METH) caused a long-lasting depressive phenotype as gauged by increased immobility 
time in the tail suspension test. It has been shown that physical exercise alleviates 
depressive symptoms.  
This study aims to further characterize the long-term depressive phenotype caused 
by a single neurotoxic METH-injection and to probe for a correlation between frontal-
cortical and hippocampal 5-HT homeostasis and the antidepressant effect of physical 
exercise.
Adult C57BL/6 mice were submitted to a treadmill exercise program (five days a 
week for seven weeks) starting 24 h post-single high dose of METH (30 mg/kg, i.p.) and 
were organized as follows (n=8/group): saline/sedentary; METH/sedentary; saline/exercise 
and METH/exercise. Then, we assessed the exploration/locomotor activity, anhedonia and 
despair (depressive-like behaviours) at a late stage of METH withdrawal (49 days) by 
open-field, splash and forced-swim tests, respectively. Frontal cortical and hippocampal 
(49 days post-METH) levels of 5-HT were evaluated by reversed-phase high performance 
liquid chromatography (HPLC). Another set of mice (16) was used to evaluate early 
impact (3 days post-METH) of METH on 5-HT hippocampal levels.  
Remarkably METH decreased the time that sedentary mice spent grooming. This 
shows that this METH dose induces anhedonia-like behavior. This further confirms that 
METH induces a long-lasting depressive-like behaviour. Remakably treadmill exercise 
reversed the time mice spent grooming in the splash test 7 weeks post-injection. This 
antidepressant-like effect was further gauged by a decreased immobility time and increased 
swimming time in the forced swimming test exhibited by both saline- and METH-
exercised animals. Additionally, exercise increased locomotor activity, exploratory 
behavior and the central distance – total distance ratio in both saline and METH treated 
mice in the open field. This is consistent with physical exercise inducing a high-mood 
state, irrespectively of drug treatment. On the other hand, METH did not alter significantly 
the motor parameters from sedentary mice. This is relevant since locomotor activity did not 
contribute to the anhedonic-like behavior seen herein.  The neurochemical analysis showed 
that METH triggered a robust 5-HT hippocampal depletion as early as 3 days post-METH, 
which recovered 49 days post-tretament. Additionally, physical exercise failed to have any 
 xi 
 
significant impact on hippocampal 5-HT levels. Moreover, neither METH nor physical 
exercise altered frontal cortical 5-HT levels. 
Importantly, we present new evidence that a 7 weeks treadmill program provided 
an antidepressant effect to METH-intoxicated mice. This exercise benefit is not associated 
with changes in the frontal cortical/hippocampal serotonergic homeostasis.  
 
 
Keywords: methamphetamine, neurotoxicity, depression, serotonin, physical exercise, 
frontal cortex, hippocampus, mice. 
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1. Drug Addiction 
 Drug addiction is a major health and social issue due to high rates of morbidity and 
mortality that are accompanied by bouts of violence and legal problems, thus imposing 
burdening individual and societal costs (Al-Haggar, 2014).  This medical and societal 
problem is considered to be a chronic, relapsing brain disorder. Particulalrly, brain 
addiction is envisaged as a malfunction of the brain’s hedonic tone regulation and the 
motivational system (Müller & Homberg, 2014). This psychiatric disorder is characterized 
by compulsive drug seeking, by their continued use despite serious negative 
socioeconomic and health consequences and marked withdrawal symptoms (Cami & Farré, 
2003; National Institute on Drug Abuse (NIDA, 2012); Koob & Volkow, 2010 and 
McAvoy, 2009).   
Collapsing the cycles of impulsivity and compulsivity yields a composite addiction 
cycle composed of three stages-binge/intoxication, withdrawal/negative affect, 
preoccupation/anticipation-in which impulsivity often dominates at the early stages and 
impulsivity combined with compulsivity dominates at the later stages (Koob & Volkow, 
2010). As an individual moves from impulsivity to compulsivity, a shift occurs from 
positive reinforcement driving the motivated behavior to negative reinforcement and 
automaticity driving the motivated behavior. These three stages are conceptualized as 
interacting with each other, becoming more intense, and ultimately leading to the 
pathological state known as addiction (Figure 1).  
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Figure 1 – Neurocircuitry schematic illustrating the combination of neuroadaptations in the brain circuitry 
for the three stages of the addiction cycle that promote drug-seeking behavior in the addicted state. Note the 
activation of the ventral striatum/dorsal striatum/extended amygdala driven by cues through the hippocampus 
and basolateral amygdala and stress through the insula. The frontal cortex system is compromised, producing 
deficits in executive function and contributing to the incentive salience of drugs compared to natural 
reinforcers. Dopamine systems are compromised, and brain stress systems such as CRF are activated to reset 
further the salience of drugs and drug-related stimuli in the context of an aversive dysphoric state (taken from 
Koob & Volkow, 2010). 
 
The binge–intoxication stage of the addiction cycle dependes upon the reinforcing 
effects of drugs that may engage reward neurotransmitters (including dopamine and opioid 
peptides) and associative mechanisms in the nucleus accumbens shell and core and then 
engage stimulus–response habits that depend on the dorsal striatum (Koob & Volkow 
2010).  
The preoccupation–anticipation (craving) stage involves key glutamatergic 
projections to the extended amygdala and nucleus accumbens from the prefrontal cortex 
(for drug-induced reinstatement of drug seeking) and from the basolateral amygdala (for 
cue-induced reinstatement of drug seeking) (Kalivas et al., 2003). Compulsive drug-
seeking behaviour is thought to engage ventral striatal–ventral pallidal–thalamic–cortical 
loops that could subsequently engage dorsal striatal–dorsal pallidal–thalamic–cortical 
loops (Vanderschuren et al., 2005), both of which are exaggerated by concomitant 
decreased activity in reward circuits (Koob et al., 2005, 2008).  
The neural substrates and neuropharmacological mechanisms for the negative 
motivational effects of the withdrawal–negative affect stage of the addiction cycle may 
involve not only disruption of the neural systems implicated in the positive reinforcing 
effects of drugs, but also recruitment of brain stress systems (Koob et al., 2008).  
Importantly, a new functional model also suggests that specific adaptations in the 5-
HT system render the nervous system susceptible to the transition to compulsive drug use 
behaviours (Müller & Homberg, 2014). 
1.1 Amphetamine-type stimulants 
Amphetamine (1-methyl-2-phenethylamine) (AMPH), which is the first member of 
a group of compounds that have similar structures and biological properties and are 
collectively called “amphetamine-type stimulants” (ATS), was first synthesized by a 
Romanian chemist named Lazar Edeleanu at the University of Berlin in 1887. However, it 
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was not used clinically until Gordon A. Alles re-synthesized the drug in the 1920s for use 
in medical settings as a bronchodilator to treat asthma and colds (Benzedrine©) (Menhard, 
2006; Berman et al., 2008; Cunha-Oliveira et al., 2013). 
The most popular ATS include methamphetamine - synthesized six years later  - 3-
4-methylenedioxymethamphetamine (MDMA) and methylphenidate (Ritalin©, Concerta©, 
Methylin©), patented in 1914 and in 1954, respectively (McDowel & Kleber, 1994; 
Morton & Stockon, 2000, McCornack & Buckley, 2006). While methamphetamine is more 
potent than the parent compound, amphetamine has moderate hallucinogenics properties 
(Cunha-Oliveira et al, 2013). 
ATS are indirect sympathomimetic and act in the nervous sytem by blocking 
transporter-mediated reuptake of biogenic amines dopamine (DA), serotonin (5-HT) and 
noradrenaline (NA) and by triggering an aberrant release of these amines from the 
presynaptic terminal into the synaptic cleft through the reversal of the amine transporters 
(Sulzer et al., 2005). Therefore, ATS produce a series of effects in mind and body 
including increasing energy, heart rate, respiration, and mental alertness, elevating mood 
and self-confidence, decreasing fatigue and sleep, producing euphoria and appetite 
suppression (Cunha-Oliveira et al., 2013; Berman et al., 2008). 
While amphetamine, METH and methylphenidate have long been used for treating 
various disorders such as attention deficit hyperactivity disorder (ADHD), narcolepsy, and 
obesity, they also may cause addition, profound effects on mental function and behavior, 
and can produce neurodegeneration (Sulzer et al., 2005; National Institute on Drug Abuse 
(NIDA; 2012); Koob & Volkow, 2010 and McAvoy, 2009).  
1.2 Epidemiology of abuse amphetamine-type stimulants 
According to the World Drug Report 2012, which was issued by UNODC, 
amphetamines (amphetamine and methamphetamine) are the prescription drugs most 
commonly abused by adolescents and young adults, and illicit amphetamines abuse ranks 
second place in young adults, with an estimated prevalence of 0.3-1.2% in 2010 (between 
14.3 million and 52.5 million consumers) (Table 1; Berman et al., 2008). 
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Table 1 – Drug Consumption in 2010, (UNODC). Information taken from World Drug Report (2012). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
In 2011, between 3.6 and 6.9 per cent of the adult population were estimated to 
have used an illicit substance in the preceding year. The prevalence of illicit drug use and 
the numbers of drug users with drug use disorders or dependence have remained stable 
(World Drug Report, 2013). While the prevalence of use of cocaine, amphetamines and 
“ecstasy”- group substances appears to have followed a declining trend between 2009 and 
2011, the prevalence of cannabis, opioids, and opiates use has risen up (Figure 2). 
Nevertheless, since 2008 there has been an overall 18 per cent increase in the estimated 
total number of people who had used an illicit substance in the preceding year, which to 
some extent reflects both an increase in the global population and a slight increase in the 
prevalence of illicit drug use.  
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Figure 2 – Trends in the prevalence of different drugs, 2009-2011. Information taken from World Drug 
Report (2013). 
 
According to World Drug Report (2013), Oceania, North America and Central 
America represent the regions with the highest prevalence of abuse of amphetamines. 
Moreover Southeast and Central Asia have been witnessing a growth in its abuse in recent 
years (Figure 3). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3 – Use of ATS in 2011 (or latest year available). Information taken from World Drug Report (2013). 
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According to the National Survey on the Use of Psychoactive Substances in the 
General Population, Portugal 2012, amphetamines use prevalence increased 0.4% from 2001 
to 2007 and youngest population is increasing its use in Portugal. The Algarve region, 
followed by Lisbon and Tagus Valley, has the highest rates of amphetamines use in both 
consumption throughout life and in continuation rates (Amaral & Guimarães 2012). 
Relatively to METH, nearly 25 million people worldwide are estimated to have used 
methamphetamine (Buxton & Dove, 2008; McAvoy, 2009), a total that exceeds the number 
of people who abuse heroin and cocaine and makes METH the second most widely abused 
drug after cannabis. This is consistent with METH having become very popular due to its 
inexpensive production, low cost of acquisition, and durability in terms of effects  (Krasnova 
& Cadet, 2009; Koob & Volkow, 2010), becoming a global epidemic (Barr et al., 2006). 
1.3 Methamphetamine and Serotonin 
1.3.1. Methamphetamine: pharmacokinetics and pharmacodynamics 
Methamphetamine was introduced in the 1930s as a bronchodilator for the 
treatment of nasal and bronchial congestion associated with colds (Meng et al., 1999; 
Guerreiro & Carmo et al., 2011), and was originally synthesized from ephedrine by the 
Japanese pharmacologist Nagayoshy Nagai in 1893, but it was not widely used until World 
War II when Japan, Germany, and the United States gave it to military personnel to combat 
fatigue and increase endurance and performance (Freese et al., 2002; Meredith et al., 
2005). METH can also be synthesized through pseudoephedrine reduction or a 
condensation of phenylacetone and methylamine (Cho, 1990, 2001).  The produced METH 
is a lipid-soluble pure base form, which is volatile and evaporates if left exposed to room 
air. The producer, therefore, tipically uses hydrochloride to convert it to 
methamphetamine-HCL powder, which is water-soluble. This METH salt is marketed on 
the streets as “speed”, “crank”, “go”, “crystal” or methamphetamine (Derlet, 1990; 
McAvoy, 2009). 
The additional methyl group found in METH confers higher lipid solubility to this 
molecule, comparatively to amphetamine, which results in greater blood brain barrier 
(BBB) permeability (Aron & Paulus, 2007), enhanced stability against enzymatic 
degradation by monoamine oxidase (MAO), and hence longer duration of action (Barr et 
al., 2006) (Figure 4). 
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Figure 4 – Chemical structure of methamphetamine (METH) (1), as well as the closely related 
psychostimulant d-amphetamine (AMPH) (2). Adapted from Barr et al., 2006. 
 
The clinical toxicology of drugs of abuse depends on the administration pathway, 
which affects its bioavailability (affecting the onset and extent of the psychotropic effects), 
the biodistribution (and therefore the exposure of target organs), and biotransformation or 
metabolism, which occurs mainly in the liver (affecting the nature and concentration of 
toxic compounds in the organism). The intensity and onset of a drug’s effects are 
determined by the rapidity of its delivery to the central nervous system (CNS). Drug users 
learn to optimize the delivery of the drug to the brain and to maximize the bioavailability 
of the drug by adapting the methods and routes of administration. (Cunha-Oliveira et al., 
2013). 
In addition to the traditional routes of administration, such as oral ingestion, 
intravenous injection, and nasal snorting, METH can be smoked and also dissolved 
sublingually, or solubilized and consumed in a beverage (Meng et al., 1999). When 
administered intravenously or smoked, small doses of METH have prominent central 
stimulant effects, acting almost immediately and causing intense pleasure (rush or flash) 
that last only a few minutes (Schepers, 2003; Kish, 2008). Thus, these two pathways 
consumption allow greater drug concentration at the sites of action at the level of the CNS 
and, therefore, provide greater potential for addiction and increase the risk of overdose 
(McAvoy, 2009). When consumed intranasally or orally, METH effect is neither so 
immediate nor so intense when compared to intravenous and inhalation routes, because of 
lower bioavailability of the former routes. After oral ingestion, METH is rapidly absorbed, 
due to being highly lipid soluble, with peak plasma levels occurring within 2.6–3.6 h 
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(Cunha-Oliveira et al., 2013). Overall, effects of METH typically persist for 4-8h, but the 
residual effects can last up to 12h (McAvoy, 2009). A typical daily dose of oral METH for 
the treatment of ADHD in children is 20-25 mg (Kish, 2008). However, the required dose 
to produce a euphoric effect, typical of this drug, is 40 to 60 mg/day. Common abused 
doses of METH are 100-1000 mg daily, and up to 5000 mg in chronic binge use (McAvoy, 
2009).  
The desired acute effects include well-being, increased alertness, increased activity, 
excitement, and decreased appetite and anxiety. METH intoxication initially produces 
excessive stimulation of the sympathetic nervous system, resulting in marked tachycardia, 
hypertension, pupillary dilation, diaphoresis, tachypnea, peripheral hyperthermia and 
hyperpyrexia (Meredith et al., 2005; Homer et al., 2008). These effects can last for several 
hours because the elimination half-line of METH ranges from 10 to 12h (Schepers et al., 
2003).  
High doses may result in restlessness and agitation, and excessive doses may 
produce stereotypic behaviors (repetitive and automatic acts). Medical problems associated 
with excessive dosages include cerebral hemorrhage, stroke, seizure, hyperthermia, 
arrhythmias, coma, and death (NIDA, 1998). Chronic METH addicts often present altered 
brain structure and function underlying deficits in attention, working memory and 
decision-making and altered behavioral and cognitive functions (Krasnova & Cadet, 2009). 
1.3.2. Serotonin Biosynthesis 
Serotonin (5-hydroxytryptamine, 5-HT) is one of the ubiquitous molecules acting 
as messengers, well known as a neurotransmitter and neuromodulator (Berumen et al., 
2011). 5-HT is phylogentically ancient and evolved prior to the apperanece of neurons 
(Muller & Jacobs, 2010). This biogenic amine was first isolated from mammalian 
organism in 1946 and then from the brain 7 years later (Hoyer et al., 2001; Hannon & 
Hoyer, 2008) and was named by Rapport et al. (1948).  
The molecular machinery governing serotonin biosynthesis across serotonergic 
neurons is well characterized and also well conserved among vertebrates and invertebrates 
(Curran & Chalasani, 2012). 
Figure 5 depicts synthesis and metabolism of 5-HT. This is a monoamine having an 
indoleamine group (Nishida, 2007) and being synthesized from L-tryptophan. This 
precursor is converted into L-5-hydroxytryptophan (L-5-HTP) by an enzymatic reaction 
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catalyzed by tryptophan hydroxylase-2 (TPH2). Then, the enzyme aromatic L-amino acid 
decarboxylase (AADC) converts L-5-HTP to 5-HT. Subsequently, vesicle monoamine 
transporters (type 2) (VMAT2) are responsible for packaging serotonin into vesicles. 
Evidence suggests that stored 5-HT is released in an even sprinkler-type fashion termed 
volume transmission, and functional concentrations of this neurotransmitter are maintained 
several microns from release sites (Doubert & Condron, 2010). Extracellular 5-HT binds to 
serotonin receptors on pre-and post-synaptic sites. 
The signal is terminated when unbound serotonin is taken back into the presynaptic 
cells by reuptake transporters (SERT), thereby limiting 5-HT extracellular concentration. 
Finally, the enzymatic degradation of brain 5-HT is mainly mediated by monoamine 
oxidase MAO-A and, in the absence of this enzyme, by its cognate isoenzyme MAO-B. 
(Bortolato er al., 2008). In addition, since MAO-B is the only isoenzyme expressed in 
platelets (Bond & Cundall, 1977), it may play an important function in the regulation of 
plasma 5-HT levels. This metabolic step origins the non-active aldehyde derivative 5-
hydroxyindoleacetic acid (5-HIAA) (Chase & Koelle, 2007; Curran & Chalasani, 2012).  
Several genes encoding the synthetic and recycling enzymes for the synthesis of co-factor 
tetrahydrobiopterin (BH4) for TPH2 in the synthesis of 5-THP are also represented in 
figure 5.  
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Figure 5 – Synthesis and metabolism of serotonin. 5-HT neurons coexpress genes directing 5-HT synthesis 
(Tph2, Aadc), reuptake (Sert), vesicular transport (Vmat2), autoreceptor signaling (Htr1a, Htr1b) and 
metabolism (Maoa, Maob). Tetrahydrobiopterin (BH4), an essential cofactor for tryptophan hydroxylase 2 
(Tph2) in the synthesis of 5-hydroxytryptophan (5-HTP), is synthesized (red pathway) de novo from 
guanosine triphosphate (GTP). It is also recycled through a regeneration pathway (orange). Genes Gch1, 
Gfrp, Ptps, Qdpr, Pcbd and Spr are directly involved in these BH4 red and orange pathways. Aldehyde 
dehydrogenase (Aldh) converts 5-hydroxyindolealdehyde (5-HIAL) into 5-hydroxyindoleacetic acid (5-
HIAA). Synaptic 5-HT modulates 5-HT neuron firing through somatodendritic Htr1a autoreceptors (5-
HT1a), 5-HT release from the presynaptic terminal through Htr1b autoreceptors (5-HT1b) and stimulates 
neurotransmission through postsynaptic 5-HT receptors (5-HT1–7). Aadc, aromatic l-amino acid 
decarboxylase; Sert, serotonin transporter; Vmat2, vesicular monoamine transporter 2; Maoa, monoamine 
oxidase; Gfrp, GTP cyclohydrolase I feedback regulator; Gch1, GTP cyclohydrolase 1; Ptps, 6-pyruvoyl-
tetrahydropterin synthase; Spr, sepiapterin reductase; Pcbd, pterin-4-alpha-carbinolamine dehydratase; Qdpr, 
quinoid dihydropteridine reductase. BH4 synthetic intermediates: H2NTP, 7,8-dihydroneopterin 
triphosphate; PTP, 6-pyruvoyl-5,6,7,8-tetrahydropterin; BH4αC, tetrahydrobiopterin-4α-carbinolamine; 
qBH2, quinoid dihydrobiopterin (Taken from Deneris & Wyler, 2012). 
 
Serotonin content in the central nervous system constitutes only 1–2% of the whole 
pool of this monoamine in the organism and it does not cross blood-brain barrier (Filip et 
al., 2005). Serotonergic CNS neurons are found primarily in nine clusters located mostly in 
the raphe nuclei of the midbrainm pons, and medulla (Figure 6a).  The more rostral raphe 
nuclei contain the principal dorsal raphe groups (B6 and B7; depicted in yellow) and the 
median raphe groups (B5 and B8; depicted in green) that project to overlapping brain areas 
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structures, including amygdala, thalamus, hypothalamus, hippocampus, and frontal cortex. 
The more caudal nuclei (B1–B3) in the medulla project axons to the spinal cord and the 
periphery. On the other hand, in the periphery, a partially separate serotonergic enteric 
neural system (ENS) exists within the gut and interacts with other CNS and peripheral 
serotonergic mechanisms (PNS), that includes lung, heart, blood-vessel and pancreatic 
tissue, as well as platelets. Notably, these tissues normally take up and store serotonin in 
vesicles, and can release it in response to local stimuli (Figure 6b).  
5-HT also play a role in the neuroendocrine serotonergic system (NSS) that 
includes the hypothalamo–pituitary–adrenocortical (HPA) system. There is an interaction 
between 5-HT and hormones such as prolactin, ACTH, corticosterone and oxytocin within 
this NSS system (Murphy & Lesch, 2008). 
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Figure 6 – 5-HT pathways. a – Central serotonergic system: CNS serotonin neuron cell-body groups in the 
nine raphe nuclei, B1–B9. The more caudal nuclei (B1–B3) in the medulla project axons to the spinal cord 
and the periphery, whereas the more rostral raphe nuclei contain the principal dorsal raphe groups (B6 and 
B7; depicted in yellow) and the median raphe groups (B5 and B8; depicted in green), which project to 
different but overlapping brain areas. b – Peripheral serotonergic system: Serotonin also functions in the 
enteric nervous system (ENS), the hypothalamo–pituitary–adrenocortical (HPA) system, the 
adrenomedullary neuroendocrine serotonin system (NSS) and the peripheral serotonin system (PSS), which 
includes the lungs, the heart, the blood vessels, the pancreas and platelets. DRN, dorsal raphe nucleus; MFB, 
medial frontal bundle; MRN, median raphe nucleus. (Taken from Murphy & Lesch, 2008). 
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Therefore, central and peripheral 5-HT system fulfill a significant role in the 
regulation of many vital functions of the organism including sleep, circadian rhythm, 
emotional, feeding, cognitive and reproductive behaviors, thermoregulation, nociceptive 
transmission, motor, endocrine, cardiovascular and respiratory functions, and intestinal 
peristalsis. Moreover, serotonin plays a major role in the etiology of the related 
pathological states, including depression, anxiety, schizophrenia, obsessive –compulsive 
and panic disorders, autism, in addition to migraine, hypertension, pulmonary 
hypertension, eating disorders, vomiting and, irritable bowel syndrome (IBS) (Filip et al., 
2005). 
1.3.3. 5-HT Receptors 
 Based on structural (amino acid sequence), biochemical (postreceptor mechanisms 
of signal transduction) and pharmacological differences, 5-HT receptors were classified 
into 7 classes and 16 different subtypes. A majority of these receptors belong to the 
metabotropic receptor family, except for 5-HT3 (5-HT3A, 5-HT3B and 5-HT3C) receptors, 
which are included in the ionotropic receptor family. 5-HT1 (5-HT1A, 5-HT1B, 5-HT1D, 5-
HT1E and 5-HT1F) receptors inhibit adenylate cyclase; 5-HT2 (5-HT2A, 5-HT2B and 5-HT2C) 
receptors stimulate phospholipase C; 5-HT4, 5-HT6 and 5-HT7 receptors stimulate 
adenylate cyclase, while the mechanism of signal transduction via 5-HT5 (5-HT5A and 5-
HT5B) has not been yet satisfactorily defined (Filip et al., 2005; Curran & Chalasani, 2012; 
Rojas et al., 2014).  
Preclinical studies have shown an increase of 5-HT1A receptor-mediated 
hippocampal transmissions after long-term treatment with selective serotonin reuptake 
inhibitors (SSRIs) and other antidepressant drug classes, suggesting that this receptor is 
involved in mood disorders. However, most selective 5-HT1A agonists developed so far 
have failed to demonstrate clinical effectiveness (Celada et al., 2004). On the other hand, 
de Angelis (2002) reviewed data presenting evidence that there is an association between 
the 5-HT2A receptor gene and psychiatric disorders including schizophrenia, tardive 
dyskinesia, major depression, suicidality, anorexia nervosa and obsessive-compulsive 
disorder. Furthermore, chronic administration of 5-HT2A antagonists results in a 
paradoxical downregulation of 5-HT2A receptors. This was suggested to be of benefit in the 
treatment of depression (Glennon & Dukat, 2002). Also 5-HT2A receptors mediate the 
primary effects of hallucinogenic drugs (Vollenweider et al., 1998; Gonzalez-Maeso et al., 
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2007). Interestingly, hallucinations and cognitive impairment are the typical clinical 
symptoms of METH psychosis.  
1.3.4. Methamphetamine action in serotonergic systems 
 Serotonin has been shown to be of essential importance for the hedonic tone 
(O’Leary & Cryan, 2010), motivational (Lee & Clifton, 2010) and reinforcement processes 
(McBride, 2010), and for learning and memory (Cassel, 2010). Accordingly, it is not 
surprising that drugs of abuse, which induce profound changes in extra-cellular 5-HT 
activity and 5-HT receptor function, change the behaviour-organizing circuitry of the brain 
directly by modulating the 5-HT system, or, indirectly, by 5-HT effects on other 
transmitter systems (Adell et al., 2010). Chronic drug exposure alters 5-HT tissue levels, 
basal extracellular activity, and responsiveness of the 5-HT system to acute drug 
administration. These effects may serve as neurochemical mechanisms for the acute 
behavioural and subjective effects. They may also contribute to the transition to addiction. 
Neurochemical studies showed that almost all psychoactive drugs with abuse 
potential acutely increase 5-HT activity throughout the brain (Muller & Homberg, 2014). 
In particular, it has been reported that METH acutely increases extracellular 5-HT levels in 
the nucleus accumbens (Nac), dorsal striatum, ventral hippocampus and prefrontal cortex 
(PFC) (Kuczenski et al., 1995; Segal et al., 1997; Rocher & Gardier, 2001; Ago et al., 
2006; Ikeda et al., 2011 and Yubero-Lahoz et al., 2012) from rodents. Studies in rodents 
further showed that the rapid increase in the concentration of 5-HT METH-induced is 
mediated by different mechanisms: in addition to stimulating the release of 5-HT, it 
inhibits its reuptake (Brodkin et al., 1993) (Figure 7). 
  Neurotoxic METH doses following an acute aberrant 5-HT release also cause long-
term deleterious effects to serotonergic neuronal systems (Krasnova & Cadet, 2009).   
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Figure 7 – The impact of METH on a serotonergic synapse (Adapted from Torres et al., 2003). 
 
In fact, experimental neurotoxic rodent models including single-day multiple-dose 
and sub-chronic METH administration have consistently shown that dysfunctional 
serotonin nerve terminals are in place (Rusyniak, 2011; Marshall et al., 2007; Belcher et 
al., 2008 Ladenheim et al., 2000; Fumagalli et al., 1998). These serotonergic changes 
include a persistent fall in the levels of 5-HT as well as 5-HT transporter (SERT) within 
several brain regions including the striatum, hippocampus, medial prefrontal and 
somatosensory cortices, hypothalamus and amygdala (Kish et al., 2009; Sekine et al, 2006; 
Gluck et al., 2001; Friedman et al., 1998; Baldwin et al., 1993; Ohmori et al., 1993; Bakhit 
et al., 1981).  Furthermore a significant decrease in SERT binding in the anterior cingulate, 
nucleus accumbens, amygdala, hippocampus, somatosensory cortex, hypothalamus, 
thalamus and septum was also reported (Armstrong & Noguchi, 2004; Guilarte et al., 
2003). 
 Finally, these neurotoxic METH dosing regimens also disturb TPH activity in the 
cortex, hippocampus and nucleus accumbens from rodents (Bakhit et al., 1981; Hotchkiss 
& Gibb, 1980; Morgan & Gibb, 1980). These experimental models are consistent with 
terminal serotonergic toxicity measured in human addicts (see section Depressive 
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behaviour during withdrawal from METH). Moreover, Chiu et al. (2014) demonstrated that 
a single-day 'binge' METH dosing regimen caused an up-regulation of 5-HT2A receptor in 
the medial frontal cortex, a brain region involved in perception, cognition and mood. This 
is suggestive that this dosing regimen, while producing detrimental effects to serotonergic 
nerve terminals, also changes 5-HT receptor density.  
It has also been shown that METH, can also cause other neurodegenerative changes 
that include dopaminergic terminal toxicity, loss of gray matter accompanied by 
hypertrophy of the white matter, gliosis (astrocytic and microglia proliferation and 
reactivity, in different brain areas), cortical and hippocampal BBB changes and oxidative 
stress (Krasnova & Cadet, 2010; Pereira et al., 2004, 2006, 2012; Bowyer & Ali, 2006; 
Bowyer et al., 2008; Martins et al. 2011, 2013; Silverstein et al., 2011; Ramirez et al., 
2009; Park et al., 2012 and Moszczynska & Yamamoto, 2011). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
CHAPTER 1 – Introduction and Aims 
18 
 
2. Depression 
Depressive disorders including major depressive disorder (MDD) rank within the 
most prevalent forms of psychiatric disorders and are among the leading causes of 
disability (Andrews et al., 2000). Today, depression is estimated to affect 350 million 
people (WHO, 2012; Wen et al., 2014) and has a 12-month prevalence of 6.6% and a 
lifetime prevalence of 16.2%, is twice as common in women as in men, and causes 
considerable impairment (Kupfer et al., 2012; Belmaker & Agam, 2008). The World 
Health Organization (WHO) estimates that depression will be the second most prevalent 
cause of illness-induced disability by the year 2020 (Murray & Lopez, 1997).  
Depression presents with depressed mood, loss of interest or pleasure (anhedonia), 
irritability, decreased energy, feelings of guilt or low self-worth, disturbed sleep or 
appetite, and poor concentration (Warner-Schmidt & Duman, 2006). Moreover, depression 
often comes with symptoms of anxiety. These problems can become chronic or recurrent 
and lead to substantial impairments in an individual’s ability to take care of his or her 
everyday responsibilities. MDD is the leading cause of suicide worldwide. Almost 1 
million lives are lost yearly due to suicide, which translates to 3000 suicide deaths every 
day. For every person who completes a suicide, 20 or more may attempt to end his or her 
life (WHO, 2012; Wen et al., 2014). Most likely, depression is caused by a combination of 
genetic, biological, environmental, and psychological factors. Thus, vulnerable and/or 
exposed individuals to certain endogenous and exogenous stressors, may develop, 
cognitive, behavioral and somatic emotional dysfunction that translates into a depressive 
syndrome (Tsuang et al. 2004).  
Although the identification of specific neural substrates for depressive disorders is 
still under investigation, hippocampus has received a great deal of attention (Warner-
Schmidt & Duman, 2006). Particularly, preclinical and clinical studies demonstrate that 
reductions of the total volume of neurons and neuronal atrophy or loss occur in the adult 
hippocampus in a context of stress and depression. Hippocampal circuitry functions 
include the control of learning and memory and regulation of the hypothalamic-pituitary-
adrenal (HPA) axis, which are altered in depression. In addition, the hippocampus interacts 
with the amygdala and frontal cortex, regions that are more directly involved in emotion 
cand cognition and thereby contribute to major symptoms of depression (Duman & 
Monteggia, 2006). 
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2.1. Depression: Focusing on 5-HT 
The 5-HT hypothesis of depression stretch back over 40 years to the discovery that 
the first generation of antidepressant drugs blocked 5-HT reuptake or metabolism as part of 
their pharmacological effect (Sharp & Cowen, 2002). Although the nature of the 5-HT 
defect remains elusive, the best evidence that 5-HT contributes to the pathophysiology of 
depression comes from studies of tryptophan depletion, which show that lowering brain 5-
HT levels can induce acute symptomatic relapse in recovered depressed patients (Cowen, 
2008; Ruhé et al., 2007; Smith et al., 1997).  
This link between 5-HT and depression provided a rich source of discoveries 
including the development of newest and popular selective 5-HT reuptake (SSRIs), which 
are currently the first choice antidepressant drug treatment. SSRIs block 5-HT reuptake, 
leading to an increase in extracellular 5-HT levels (Blier, 2001; Quesseveur et al., 2013). 
This monomine increase activates feedback mechanisms mediated by 5-HT1A (cell body) 
and 5-HT1B (terminal) autoreceptors, which, respectively, reduce the firing in dorsal raphe 
5-HT neurons and decrease the amount of 5-HT released per action potential, resulting in 
attenuated 5-HT neurotransmission in regions such as frontal cortex and hippocampus. 
Long-term treatment desensitizes the inhibitory 5-HT1 autoreceptors, and 5-HT 
neurotransmission is enhanced. The time course of these events is similar to the delay of 
clinical action. 
Overall SSRIs seem to allow what might be an important convergence of 
neurobiological and psychological explanations of the role of 5-HT in antidepressant 
action and depression (Sharp & Cowen, 2002). The oldest class of antidepressant 
medications is monoamine oxidase inhibitors (MAOIs). Tricyclics are other types of older 
antidepressants. Tricyclics antidepressants (TCA) inhibit non-selectively 5-HT and 
noradrenaline uptake (Katzung et al., 2001). Interestingly, previously referred hippocampal 
alterations can be reversed by chronic antidepressant treatment (Lee & Kim, 2010). 
However the nature of post-synaptic signaling and the contribution of glia to the 
antidepressant pharmacological effects are largely unknown. Both TCAs and MAOIs are 
potentially lethal in overdose, require titration to achieve a therapeutic dose, have serious 
drug interactions and have many troublesome adverse effects. Consequently, these drugs 
are now reserved for patients who do not respond to other agents.   
Moreover, due to its long therapeutic time delay, low rates of remission, and 
exposure to relevant side effects, including gastrointestinal, hepatic and sexual, the 
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research for more effective agents in the treatment of these disorders has been greatly 
stimulated (Manji et al., 2008; Berton & Nestler, 2006). For example, physical exercise, 
being able to relieve symptoms of depression (APA, DSM-V-TR, 2013), seems to be a 
non-pharmacological alternative strategy in the treatment of depression. 
Finally, although not addressed in our work, other hypothesis pointing towards a 
role for other neurotransmitters including NA, inflammation, neuroplasticty and epigenetic 
regulation have also been implied in depressive disorders (Han & Yun, 2014; Massart et 
al., 2012; Krishnan & Nestler, 2008). 
2.2. Depressive behaviour during withdrawal from METH 
Mood disorders, including depression and bipolar disorders, are the most common 
psychiatric comorbidities among patients with substance use disorders (Quello et al., 2005; 
NIH, 2011). For example, diminished interest or pleasure in rewarding stimuli or 
anhedonia is one of the core symptoms of both depression and psychostimulant 
withdrawal. Importantly, METH withdrawal and major depression share many behavioral 
commonalities in humans (Cryan et al., 2003). In detail, repeated METH use produces a 
withdrawal syndrome marked more by psychiatric complaints than by physical 
manifestations. These withdrawal syndrome typically manifests as anxiety, depression with 
severe dysphoria, irritability and melancholia, social isolation, fatigue with hypersomnia, 
psychomotor dysfunction, mood disturbances, impaired social functioning, intense craving 
for the drug and even paranoia or aggression, as well as attention deficits and memory in 
making decisions (London et al., 2004; Meredith et al., 2005; Darke et al., 2008; Homer et 
al., 2008, Sutcliffe et al., 2008; Krasnova & Cadet, 2009; Daniulaityte et al., 2010; 
Guerreiro & Carmo et al., 2011).  
Although the severity of the abstinence syndrome appears to be related to the 
frequency of use, it tends to resolve spontaneously, while the depressive symptoms persist 
for months or years after discontinuation of drug use (Barr et al., 2002; Cami & Farre, 
2003). Moreover, the prevalence of depression among METH users is higher than the 
general population, with the majority of METH users reporting a lifetime history of 
depression and over a third reporting a lifetime diagnosis of depression. However, the 
temporal relationship between depression and METH use is unclear. In fact, it is unknown 
whether experiencing depressive symptoms promotes METH use, whether depression 
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results from or is enhanced by METH use, or whether it is bidirectional (Sutcliffe et al., 
2009).  
Addressing this issue is clinically relevant as it may inform about treatment options 
for both METH dependence and mental health (Pecke et al., 2005). Therefore, the 
examination of the behavioral effects of METH withdrawal in rodents may provide 
insights into the neurobiological mechanisms underlying both disorders. For example, 
Cryan et al. (2003) showed that drug-withdrawn rodents displayed increased immobility in 
forced swim and tail suspension tasks (24 hours after deprivation of METH; 5 mg/kg/day 
for 7 days), suggesting that there is a depressive-like behavior. Recently, Jang et al. (2013) 
found that chronic METH self-administration produced a depressive-like withdrawal state 
in rats during early withdrawal.  
We also recently provided novel data that a single high neurotoxic dose of METH 
(30 mg/kg i.p.) evoked depressive-like behavior as gauged by increased immobility in the 
tail-suspension task at 3 days and 7 weeks post-METH treatment (Silva et al., 2014). This 
negative affect-like behavior was underlined by prolonged frontostriatal dopaminergic 
deficits including DA and TH. Importantly we also demonstrated that this METH regimen 
evoked 5-HT depletion in frontal cortex at 3 and 49 days post-METH injection. However 
we failed to probe METH impact in hippocampus. This is suggestive that this 5-HT 
homeostasis disruption might also contribute to the depressive-like behavior. 
Interestingly, abstinent METH abusers showed reduced brain 5-HT transporter 
density and cerebral metabolic abnormalities associated with depressive symptoms 
(London et al., 2004; Sekine et al., 2006; Panenka et al., 2012). It is worthwhile stress that 
psychostimulant withdrawal seems to provide the basis for the development of an animal 
model of depressive symptoms, such as despair, anhedonia, lethargy and anxiety (Paulson 
et al., 1991; Cryan et al., 2003), thus allowing the screening of new pharmacological or 
non-pharmacological approaches (Barr et al., 2002). This is particularly relevant since 
there is no reliable treatment that can reverse the effects of psychostimulant withdrawal 
rapidly and completely at present. 
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3. Physical Exercise 
3.1. Physical Exercise: a non-pharmacological approach in 
depressive disorders 
Data from epidemiological studies suggest a strong association between physical 
inactivity and high levels of depressive symptoms (Farmer et al., 1988; Camacho et al., 
1991; Conn et al., 2010). In fact, low levels of physical activity lead to an increase in 
symptoms of depression in young (Motl et al., 2004; Strong et al., 2005; Neissaar et al., 
2011) and older adults (Blumenthal et al., 1999; Lampinen et al., 2000; Brosse et al., 2002; 
Conn et al., 2010).  
On the other hand, human studies suggest that exercise may be useful in the 
prevention and treatment of psychiatric disorders such as depression (Conn et al., 2010) 
and anxiety disorders (Dunn et al., 2010), Furthermore, Lawlor & Hopker  (2001) 
reviewed data suggesting that exercise has antidepressant effects that are of the same 
magnitude as cognitive therapy in the management of mild-to-moderate mental health 
diseases. It also was demonstrated that the antidepressant effects of exercise were 
prolonged beyond the period of treatment with benefits until 6 (Babyak et al., 2000) and 21 
months (Singh et al., 2001) after stopping the exercise. Trivedi et al. (2006) showed that 
exercise reduced depressive symptoms or reduced side effects when combined with a 
pharmacological approach. In addition, Frazer et al., 2005 indicate chronic exercise as one 
of the best non pharmacological treatments for depression, besides the fact that it is low 
cost, have positive effects on cardiovascular disease risk, and be a potential prevention 
agent for future depressive episodes. Others further proposed that exercise was as effective 
as antidepressant medications (Blumenthal et al., 1999; Strawbridge et al., 2002). 
However, habitual physical activity has not been shown to prevent the onset of depression 
(Paluska & Schwenk, 2000). One possible neurobiological mechanism underlying the 
positive effects of exercise is the increased synthesis of 5-HT (Matta et al., 2013). This is 
the studied hypothesis in the present work.  
Despite the relationship between the efficacy of physical exercise in reducing the 
symptoms of depression already has been widely documented, there is still a lack of data 
on the type of physical exercise that induces better antidepressant response (Mead et al., 
2008). On one hand, aerobic exercise is associated with higher benefits (Ernst et al., 2006). 
For example, a program of 12 weeks of aerobic exercise functioned as an effective 
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treatment for depression of mild to moderate severity (Dunn et al., 2002, 2005).  
Furthermore, increased aerobic exercise or strength training has been shown to 
significantly reduce depressive symptoms (Paluska & Schwenk, 2000; Craft & Perna, 
2004). On the other hand, Greenwood et al. (2013) were the first to suggest that individuals 
who have made forced physical exercise can still benefit from its protective effects against 
psychiatric disorders related to stress.   
Although effective pharmacological interventions are available, depression remains 
inadequately treated.  Thus, physical exercise seems to be a non-pharmacological tool in 
the treatment of psychiatric diseases such as depression and, therefore, in the promotion of 
a better mental health. 
A cautionary note should be added. In fact, it was suggested that excessive physical 
activity may lead to overtraining and generate psychological symptoms that mimic 
depression (Paluska & Schwenk, 2000). 
3.2. Physical Exercise: managing METH addiction and 
neurotoxicity 
To date, there are no medications approved for the treatment of METH dependence 
(Mooney et al., 2014 and Karila et al., 2010). Behavioral approaches, such as cognitive 
behavioral therapy and contingency management, have proven modestly effective and 
remain the standard treatment. However, there are substantial proportions of individuals 
dropping out early in the treatment (Rawson et al., 2004; Peirce et al., 2006; Roll et al., 
2006; Rawson et al., 2006).  
Notably, there is an increasing amount of literature suggesting that physical 
exercise is as a potential treatment for METH-dependent individuals (Mooney et al., 2014). 
For example, it was demonstrated that physical exercise improved cognitive deficits found 
in chronic METH users (Simon et al., 2000). Recently, a study in humans reported for the 
first time that 8-weeks of endurance and resistance exercise training triggered positive 
adaptations on individuals recovering from METH-dependence, such as substantial 
improvements in aerobic exercise performance, muscle strength and endurance, and body 
composition with exercise training. These changes are consistent with those seen in the 
general population, suggesting that structured and supervised exercise training should be 
considered as part of the overall treatment plan in recovering METH patients (Dolezal et 
al., 2013). Another study examined whether a combination of aerobic exercise and 
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resistance training could facilitate relapse prevention and maintenance of abstinence from 
METH after discharge from residential treatment (Mooney et al., 2014). These authors 
suggested that exercise may provide a reinforcing behavior that offers an alternative to 
drug use as a means of enhancing positive mood states.  
Furthermore, exercise may have a salutary effect on reducing cardiovascular risk 
factors, such as hypertension, that are associated with METH use (Mooney et al., 2009; 
Turnipseed et al., 2003). Exercise also improves sleep (Youngstedt et al., 2005) and 
performance on cognitive tasks, which may be impaired in METH users and in long-term 
METH users in early phases of abstinence (Mooney et al., 2014). 
On the other hand, O’Dell et al. (2012) demonstrated that running wheel exercise 
ameliorates methamphetamine-induced damage to forebrain DA and 5-HT terminals in 
rats. Moreover, it was shown that exercise protected against cerebrovascular toxicity of 
METH mice (Toborek et al., 2009). Remakably, we have recently shown that treadmill 
exercise reversed the long-lasting behavioural phenotype triggered by single-METH 
neurotoxic dose as demonstrated by decreased immobility time in the tail suspension test 
when compared to sedentary METH-intoxicated mice (Pereira et al., 2014, unpublished 
data). 
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4. Aims of this thesis 
This study aims to further characterize the long-lasting depressive phenotype 
caused by a single neurotoxic METH-injection and to probe for a correlation between 
frontal-cortical and hippocampal 5-HT homeostasis and e the antidepressant effect of 
physical exercise.
   
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
CHAPTER 2 
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1. Animals 
In this investigation we used 44 C57BL/6 male mice (10 weeks old, 21-26 g, 
Charles River Laboratories, Barcelona, Spain) (Figure 8), divided into 11 cages (4/cage) 
and maintained in the animal house of the Faculty of Medicine, University of Coimbra 
(FMUC) under controlled environmental conditions (temperature, 22 ± 1 ° C, humidity 50 
± 10 %, light cycle, 12/12 hours), with food and water provided ad libitum. Their weight 
was monitored weekly to assess the evolution of the different experimental groups. 
All experimental procedures followed the rules imposed by the Standards of 
Animal protection techniques used for experimental and other scientific purposes 
(Ordinance No 129/92 of 6 July), as well as the standards of the European Convention on 
Animal Welfare (Ordinance No 1005/92) and in accordance with the guidelines of the 
European Community (2010/63/EU). All efforts to minimize animal suffering and to use 
the smallest possible number of animals were made. 
 
 
 
 
 
 
 
Figure 8 – Example of a C57BL/6 mouse. Taken from http://jaxmice.jax.org/strain/002020.html.  
2. Drugs and Chemicals 
We were issued permission to import methamphetamine.HCL (METH) for Sigma-
Aldrich (St. Louis, MO, USA9 by INFARMED, Portugal (National Authority of 
Medicines and Healths Products). Standards for serotonin (5-HT) were purchased from 
Sigma-Aldrich. The other used chemicals (ultrapure and pro analysis quality) were 
purchased from Sigma-Aldrich and Merck AG (Darmstadt, Germany).  
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3. Experimental Design 
32 animals were randomly divided into 4 groups, with 8 animals per group: (1) 
sedentary saline group (Cont/SED), (2) exercise saline group (Cont/EX), (3) METH 
sedentary group (METH/SED) and (4) exercise METH group (METH/EX) (table 2). The 
animals were previously identified with ink stripes on the tail and housed in their 
respective cages, having been subjected to an adaptation period of 2 weeks in controlled 
vivarium conditions (mentioned above). The weight of the mice was recorded weekly, 
using an analytical balance (Kern CB 6 K1, Germany). However, the weighing was done 
daily on subsequent administration of the neurotoxin week. 
 
Table 2 – Experimental groups and number of mice used (n). 
 
  Mice (n=32) 
Exercise (n=16) Sedentary (n=16) 
METH/EX 
(n=8) 
Cont/EX  
(n=8) 
METH/SED 
(n=8) 
Cont/SED 
 (n=8) 
3.1. Treadmill adaptation 
Herein, two treadmills were used [the LE8700 model, serial number 2187/07 and 
the LE8706 model, serial number 8589/04, both with 50 W, 110/120 V and 50/60 Hz; 
Panlab, SL, Barcelona, Spain,] for the implementation of aerobic exercise. Separating each 
lane with transparent acrylic, thus diminishing the width of each corridor and resized these 
models, which are suitable for mice. Therefore, it was possible to exercise 4 mice per 
treadmill at the same time (Figure 12). 
Mice submitted to exercise (SAL/EX and METH/EX groups) were putin a daily 
workout plan aiming to foster treadmill adaptation for 2 weeks (5 days/week). The 
adaptation protocol consisted in four phases (Figure 9), with a progressive increase in the 
total time (20 min at the beginning to 40 min on the last week) and intensity (daily 
maximum speed of 20 to 30 cm/s) of each training session until achieving the values used 
in the exercise protocol. 
The treadmill was turned on to a minimum speed of 5cm/seg only after and the 
animals were placed in the lanes. Thereafter, the speed was gradually increased (about 
1cm/seg) until the desired speed, thus comprising the initial stage of the session - heating 
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phase. After the time and intensity required for the training session were applied, the speed 
periodically decreased at the same rate until the treadmill is turned off -– cooling phase. 
Both phases are relevant because they aim to prevent injury. 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 9 – Mice adaptation protocol to treadmill. Tr, training and R, rest. 
3.2. Methamphetamine administration 
Subsequently to the adaptation protocol to the treadmill and prior to the beggining 
of the exercise protocol, all mice were weighed again to calculate METH dose for each 
mouse.  
Control groups (SAL/SED and SAL/EX groups) were administered a saline 
solution (NaCl 0.9%, 250μl.), while METH/SED and METH/EX groups were injected 
with 30 mg/kg methamphetamine.HCL (METH; 3mg/ml). Animals were dosed with a 
single intraperitoneal injection (i.p.) (Figure 10). We have recently demonstrated that this 
dose induces astrogliosis, as well as dopaminergic and serotonergic terminal toxicity to 
striatal-cortical regions in mice as soon as 3 days post-METH (Pereira et al. 2012; Silva et 
al. 2014). However, we failed to characterize serotonergic homeostasis in hippocampus 
from these neurotoxic models at this time-point. Therefore we used another set of 12 mice 
to probe METH-impact on hippocampal total 5-HT levels at 3 days post-injection. Half of 
the animals were injected with saline.  
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Figure 10 – Intraperitoneal administration of a single dose of METH (30 mg/kg). 
 
 
After injection, the animals were carefully observed, at 0.5, 1 and 3 time-points. 
Animals receiving this neurotoxin were extremely agitated, which is consistent with what 
is reported in the literature (Meredith et al., 2005). 
Two of the mice belonging to the METH/EX group were found dead the following 
day. This may be due to hyperthermia caused by METH. 
Infarmed Portugal (National Authority of Medicines and Health Products IP) issued 
necessary authorizations for FMUC to acquire METH from Life Science and High 
Technology Company Sigma-Aldrich (St. Louis, MO, USA). 
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3.3. Exercise protocol 
 
Figure 11 – Physical exercise protocol for the respective exercise groups, SAL/EX and METH/EX. Ex, 
exercise; R, rest and S, sacrifice. 
 
Twenty-four hours follwoing METH/NaCl administration, the exercise groups 
(SAL/EX and METH/EX) underwent a protocol of daily running (Figure 11), 5 days per 
week for 7 weeks (35 days of exercise) according to the following planning: 1) 5 min 
heating at 20 cm/s; 2) 30 min of running at 30 cm/s; 3) 5 min cooling at 20 cm/s. Exercise 
was always performed on the same morning period. The inclination of the treadmill was 
always null (0%). Mice were prompted to run by gentle manual strokes instead of using 
electric shocks, thus minimizing stress imposed to animals, which is considered to be a 
possible factor stress that is not usually associated with exercise. 
 
Protocol: 
 
- Ex: Velocity – 20cm/s – 5 min; 30cm/s – 30 min; 20cm/s – 5 min 
-     R: Rest 
- BT: Behavioural test 
- BT/S: Behavioural test/Sacrifice 
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Figure 12 – Mice training on a treadmill separated by acrylic divisions, providing four individual 
lanes. 
 
The animals in the sedentary groups ran only once a week for 10 minutes at 
minimum speed of 5 cm/s to experience the same stressful conditions felt by the animals of 
the exercise groups. Woods et al. (2003) proposed that the engine noise of the treadmill, 
vibration, treadmill texture, water and food deprivation and frequent handling of animals 
are some of the stressful factors. 
4. Behavioural Tests 
Behavioural tests, Open-field (OF), Splash and Forced-swim test (FST) were 
performed, 48 and days after administration of METH (30 mg/kg, i.p.) or saline to assess 
mice emotional states. The first test was performed in the first day, whereas the Splash and 
the FST were conducted on the second day.  
Tests were all performed between 9 and 17h, in a sound-attenuated room lit with 
low intensity Light (12 lx). Mice were transferred to this room 1h before the start of the 
testing to get used to the environment. The behaviour was monitored by a video camera 
positioned above the equipment and the images were subsequently analyzed with the 
system of video monitoring ANY Maze (Stoelting Co., Wood Dale, IL, USA) by an 
experienced experimenter who was unaware of the experimental group being tested. 
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4.1.  Open-field test 
The open-field (OF) test procedure consists of subjecting an animal to an unknown 
environment from which escape is prevented by surrounding walls (Walsh and Cummins, 
1976). We applied herein a 5-min test length to assess the effect of treadmill exercise on 
novel environment exploration and general locomotor activity in METH-treated METH 
mice (Bayley & Crawley, 2009; Machado et al., 2012.  
Mice were individually placed in the center of a wooden box (40×40×50 cm
3
), and 
the following behavioral items were recorded: horizontal locomotion (total distance 
travelled), central distance, central-total distance ratio, number of rearing (sometimes 
termed vertical activity) and average speed. Tipically, mice prefer spontaneously the 
periphery of the apparatus to activity in the central parts of the open field (Figure 13). 
Indeed, rodents walk close to the walls, a behavior called thigmotaxis. Therefore, increase 
of time spent in the central part, as well as of the ratio central/total locomotion are 
indications of anxiolytic-like behavior (Prut & Belzung, 2003). 
The apparatus was cleaned with a solution of ethanol 10% between tests in order to 
remove animal odors or clues. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 13 – Open Field test: mice in open-field test apparatus. 
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4.2.  Splash test 
This pharmacological test was adapted from Yalcin et al. (2005) and was used 
herein to evaluate the impact of treadmill exercise on grooming behaviour in mice injected 
with METH as an index of self-care and motivational behaviour phenotype of the 
experimental groups. For this purpose, 10% sucrose solution was squirted on the dorsal 
coat of mice in their home cage.  Following this viscous solution dirtying the mice fur, 
animals initiate grooming behaviour. The latency for the first grooming and the total 
grooming time were recorded in an acrylic chamber (40 x 40x 40 cm) during 5 minutes 
(Figure 14).  
Grooming bouts were recorded including nose/face grooming (strokes along the 
snout), head washing (semicircular movements over the top of the head and behind the 
ears) and body grooming (body fur licking) (Kaluelf & Tuohimaa, 2004). Anhedonic 
symptoms were characterized by increased latency (midle time between spray and 
initiation of grooming) and decreased time spent grooming (d’Audiffret et al., 2010).   
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 14 – Splash test: A - mice in the cage 2 is grooming his dorsal coat in his home cage; B - schematic 
illustration of dorsal mice grooming. Adapted from http://mybrainnotes.com/bdd-trichotillomania-skin-
picking.html.  
B 
A 
1 2 
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4.3. Forced-swim test 
The Forced-swim test (FST) has been used as a model predictive of antidepressant 
effect (Cryan et al., 2002). The test procedure was carried out according Porsolt et al. 
(1977) with some modifications. Mice were individually forced to swim in an open 
cylindrical container (21 cm height × 12 cm internal diameter) containing fresh water till a 
height of 15 cm at 23±1 °C; the total duration of immobility was recorded during a 5 
minute period (Figure 15). The water was changed and the cylinder rinsed with clean water 
after each mice. A trained observer that was blind to the treatment measured the 
immobility time.  
During the 5 min swimming test session, the following behavioral responses were 
recorded by a trained observer: the immobility time (i.e. the time spent floating in the 
water without struggling, making only those movements necessary to keep its head above 
water), swimming (time spent actively swimming around in circles), and climbing 
behavior, which is defined as upward directed movements of the forepaw along the 
cylinder walls. This test involved the scoring of active (swimming and climbing) and 
passive (immobility) behavior when mice were forced to swim in a cylinder from which 
there is no escape. A decrease in the duration of immobility time and an increase in 
swimming time is indicative of an antidepressant-like effect (Porsolt et al., 1977), while 
time of climbing was used as a predictor of altered motor activity scored directly in the 
forced swimming test (Vieira et al., 2008). Typically, after the initial 2-3 minutes of 
vigorous activity the animals showed a period of immobility by floating with minimum 
movements. An animal is considered to be immobile whenever it remained floating 
passively in the water in a slightly hunched but up right position, its nose above the water 
surface (Khulbe et al., 2013). 
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Figure 15 – Forced-swim test. Mice placed into an open cylindrical container. 
 
5. Frontal Cortex and Hippocampus Isolation 
Following behavioural tests, animals were sacrificed by cervical dislocation and 
decapitated  - that is 48 h after the end of the protocol of physical exercise (on the second 
day of rest) or 49 days after administration of METH/saline. 
The brains were rapidly removed, and hippocampus and the frontal cortex were 
dissected on icebased on the coordinates for the mouse brain described by Paxinos & 
Franklin (2004). The biological samples were immediately frozen in dry ice and stored at -
80 ° C until 5-HT analysis by high pressure liquid chromatography with coulometric 
electrochemical detection (HPLC). 
6. Determination of 5-HT by HPLC 
A reversed-phase high-performance liquid chromatography (HPLC) method with 
coulometric electrochemical detection was applied to quantify 5-HT brain levels (Figure 
17) (Pereira et al., 2011). The used equipment is illustrated in figure 16 and included a 
Gilson pump (model 307), an autosampler Gilson (model 234; 50mL loop), a detector 
Gilson (coulometric) and v5.11 software. 
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Figure 16 – HPLC system used to quantify 5-HT in this study. A - Gilson pump, B - autosampler Gilson, C - 
detector Gilson and D - v5.11 software. (Picture taken at Laboratory of Pharmacology and Experimental 
Therapeutics, Faculty of Medicine, University of Coimbra).  
 
 
 
Figure 17 – Chromatogram illustrating a 5-HT peak relative to a frontal cortex sample from a METH/EX 
mice group. The obtained 5-HT retention time was between 8 - 9 min. 
 
 
B D 
A 
C 
5-HT 
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perchloric acid 0.2 M. The homogenates were centrifuged (13,000 rpm for 7 min, 4 ° C) 
and filtered with 0.22 mM Nylon microfilter (Spin-X ® Centrifuge Tube Filter, Costar at 
10,000 rpm for 4 minutes, 4° C). The pellets were resuspended in NaOH 1 M and used for 
quantification of the protein by the bicinchoninic acid method (BCA) and reading by 
ELISA. The filtered supernatants and the pellets were stored at -80 ºC. 
Serotonin was separated on a reversed-phase, Grace Platinum EPS C18 column ® 
(4.6 x 150 mm, particle size: 5 mM) with a mobile, degassed and filtered phase consisting 
of monopotassium phosphate (25 mM), 1-heptanesulphonic acid (0.4 mM), EDTA (50 
µM), 3% acetonitrile (pH 2.5). The flow rate was 1 mL/minute. Samples were quantified 
by an analytical cell (model 5011, ESA Analytical, Dorton Aylesbury, Buckinghamshire, 
UK) attached to a Coulochem-II electrochemical detector (ESA, Analytical).  The 
analytical cell was set at E1=+250 mV (sensitivity - 200 nA). 
The concentration of 5-HT in each sample was calculated taking as reference the 
standard curves of 5-HT. The results were expressed in ng/mg protein. 
7. Statistical analysis 
The results are expressed as mean ± standard error (SEM). Body weight data were 
analysed by one-way ANOVA followed by Newman–Keuls multiple comparison.  
Behavioural and neurochemical data were analysed by two-way ANOVA (drug x 
exercise) followed by Bonferroni multiple comparison. Significant differences were 
defined at P<0.05. The statistical analyses were performed using GraphPad Prism 6.0 
software. 
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1. Effects of methamphetamine and/or chronic physical exercise 
on body weight 
 The mice body weight significantly increased in all groups (P<0.05) over the total 
duration of the experimental protocol (61 days, Figure 18 A,B).  Interestingly, mice body 
weight from each group is not significantly different from each other at the last time 
evaluated (P> 0.05) (Figure 18 B). 
 
 
 
 
 
 
 
 
 
 
 
Figure 18 – A: Evolution of the mice body-weight over 61 days (total duration of experimental protocol). B: 
Mice body-weight at 3 different time-points: day 1: beginning of training; day 14: METH administration; day 
61: last day of physical exercise program. The results are expressed as mean ± S.E.M. of 6-8 animals per 
group. Control sedentary mice body-weight at the 61 days is statistically different from the other time points 
($P<0.05). #P<0.05. Statistical analysis was performed using one-way ANOVA followed by Newman–Keuls 
multiple comparison. 
A 
B 
CHAPTER 3 – Results 
 
41 
 
2. Effect of treadmill exercise on general exploratory 
locomotion in METH-exposed mice 
2.1.  Open-field test 
 Mice activity was quantified in the open-field over 5 minutes to assess novel 
environment exploration 49 days post-METH injection. METH-sedentary mice showed 
normal total distance (Figure 19 A) and central distance travelled (Figure 19 B), normal 
central distance–total distance ratio (Figure 19 C), number or rearings (Figure 19 D) and 
average speed (Figure 19 E). This is suggestive that the general exploratory behavior of 
these animals is not statistically different from that showed by the respective controls 
(SAL/SED) (P>0.05). Exercise increased all these measured parameters in both METH and 
Cont (P<0.05). This is highly suggestive that physical activity enhanced both locomotor 
activity and exploratory behavior. 
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Figure 19 – Effect of treadmill exercise on the locomotor activity and exploratory behavior (open field test) 
in mice injected with a single dose of METH (30 mg/kg, i.p.). The figure shows the total and central area 
distances traveled (A,B), central distance-total distance ratio (C), number of rearings (D) and the average 
speed (D) in the arena at 49 days post-injection. The results are expressed as mean ± S.E.M. of 6-8 animals 
per group. #P<0.05 versus respective sedentary animal controls, using a two-way ANOVA with Bonferroni 
post-test. 
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3. Effect of treadmill exercise on depressive-like behavior in 
METH-exposed mice 
3.1. Splash test 
Mice anhedonic-like phenotype was assessed using the Splash test that allowed the 
measurement of grooming behavior for 5 minutes, 49 days post-injection.  
A two-way ANOVA test disclosed a significant drug x exercise interaction 
(F1,23)=5,92, P<0,05) in grooming time. A post-hoc analysis showed that METH-
sedentary mice exhibited reduced grooming time when compared with saline-sedentary. 
Notably, METH-exercised mice not only showed similar grooming time when compared 
with its exercised control (P<0.05) but also had higher grooming time when compared with 
METH-sedentary mice (P<0.05) (Figure 20 B). Although METH-sedentary mice showed a 
tendency to have an increased latency to grooming it did not attain significance when 
compared with their sedentary controls (Figure 20 A).   
 
 
 
 
 
 
 
 
Figure 20 – Effect of treadmill exercise on grooming behavior (splash test) in mice injected with a single 
dose of METH (30 mg/kg, i.p.). The figure shows the latency to grooming (A) and grooming time (B) in the 
splash test at 49 days post-injection. The results are expressed as mean ± S.E.M. of 6-8 animals per group. 
*P<0.05 versus SAL/sedentary; #P<0.05 versus METH/sedentary, using a two-way ANOVA with 
Bonferroni post-test. 
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3.2. Forced-swim test 
Mice despair-like behaviour was probed using forced swim-test for 5 minutes, 49 
days post-METH injection.  
 METH-sedentary mice did not show a despair-like behavior as gauged by 
immobility, swimming and climbing times not being statistically different from those 
shown by their respective controls (SAL/SED) (P>0.05; Figure 21 A, B, C). Notably, 
treadmill exercise decreased the immobility time (Figure 21 A) and increased the 
swimming time (Figure 21 B) in both SAL and METH groups when compared to their 
sedentary controls (P<0.05; Figure 22 A, B, C). Nonetheless exercise failed to change the 
climbing time (C) relatively to sedentary groups (P>0.05; Figure 21 C).  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 21 – Effect of treadmill exercise on the depair-like behavior (forced swimming test) in mice injected 
with a single dose of METH (30 mg/kg, i.p.). The figure shows the immobility (A), swimming (B) and 
climbing (C) times in the forced swimming test at 49 days post-injection. The results are expressed as mean ± 
S.E.M. of 6-8 animals per group. #P<0.05 versus respective sedentary control animals using a two-way 
ANOVA followed by with Bonferroni post-test. 
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4. Effect of treadmill exercise on 5-HT total content in frontal 
cortex and hippocampi from METH-exposed mice 
Serotonin is a neurochemical fingerprint from depressive-like behavior and was 
measured herein by HPLC. Hippocampal 5-HT levels were quantified 3 and 49 days post-
METH injection. Frontal cortical 5-HT levels were only determined at the final end-point. 
METH imposed a hippocampal 5-HT depletion as seen in Figure 22 A. However, neither 
drug nor exercise had a significant effect on cortical and hippocampal 5-HT total content 
(P>0.05; Figure 22 B,C).  
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 22 – Effect of treadmill exercise on hippocampal (A,B) and frontal cortical (C) serotoninlevels (5-HT 
measured from mice at 3 (A) and 49 days (B, C) post-METH injection). The results are expressed as mean ± 
S.E.M. of 6-8 animals per group. *P<0,05 versus saline-treated animals using unpaired t-test.  
A: 3 days post - METH injection 
B: 49 days post - METH injection C: 49 days post - METH injection 
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Discussion 
Although clinical studies have shown the relevance of the symptoms of depression 
in consumers of METH on abstinence (Glasner-Edwards et al. 2009 and Volkow et al., 
2001; Rusyniak, 2011), this psychiaytric abnormality in METH abuse context has been 
scarcely studied. In fact, the study of the long-term mood behavioural and underlying 
neurochemical consequences of METH consumption is still poorly characterized. 
Therefore herein we offer a comprehensive characterization of the long-term emotional 
state of mice following a single-neurotoxic dose of METH using Splash, forced swim test 
(FST) and open field (OF). We want ultimately to robustly confirm that METH induces 
depressive-like behaviour. We further aimed to establish a relationship between 5-HT 
homeostasis in frontal-cortex and hippocampus and the putative antidepressant effect 
induced by physical exercise. 
The single high METH dose regimen that we use in the present study recapitulates 
the detrimental effects found in METH users including corticalstriatal dopaminergic and 
astroglial dysfunction (Cappon et al., 2000; Imam & Ali, 2001; Xu et al., 2005; Zhu et al., 
2005; Krasnova & Cadet, 2009; O’Callaghan et al., 2008; Kitamura et al., 2010; Sailasuta 
et al., 2010; Pereira et al., 2012; Silva et al., 2014). In addition, this model reduces the 
inherent complexity present in repeated dosage regimens and reduces the occurrence of 
seizures and high mortality seen with multiple doses regimen (Davidson et al., 2001; 
Miller & O’Callaghan, 2003). In fact, in the present study, only two mice died and none 
showed convulsions or weight reductions. It is noteworthy to stress that animals from the 
exercise group started to put on weight following 14 days of adaptation to the treadmill. 
This might suggest that the animals had to cope with a stressful situation that they 
overcome as shown by weight evolution and behavioral phenotype (see above).   
The splash test is a direct measure of self-care and motivational behavior and has 
been reported to probe for mood disorders in rodent models. We observed for the first 
time, that the METH regimen induced a decreased grooming behaviour in the METH-
sedentary mice, when compared to the respective control, which is indicative of a long-
term anhedonic-like behaviour that mimics apathy observed in clinical depression 
(Willner, 2005). Furthermore, METH-sedentary mice showed a tendency to had increased 
latency to grooming, further indicating loss of self-care and motivational behavior. This is 
consistent with the fact that some chronic METH users exhibit an anhedonic and 
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depressive behavior in a persistent manner after a few years follwoing the end of 
consumption (Rawson et al. 2002). Physical exercise, by itself, didn’t alter the grooming 
time of the mice, but recovered grooming-time in METH-intoxicated mice. This result 
suggests that the practice of physical exercise is a non-pharmacologic strategy with anti-
anhedonic potential (Willner et al., 2005). We further analysed negative mice behaviour 
using FST. This test was designed by Porsolt, as a primary screening test for 
antidepressants with a strong predictive validity (Porsolt et al., 1977). Porsolt et al. (1977) 
further proposed that the immobility time observed in this test reflected a state of lowered 
mood or hopelessness in animals (Cryan et al., 2002).  
FST showed that METH-sedentary mice exhibited normal immobility, swimming 
and climbing times when compared with their sedentary controls.  This is apparently 
contractidory with METH-intoxicated mice having increased immobility time in the TST 
at the same time-point (Silva et al., 2014). However, it was demonstrated that TST is more 
sensitive than FST in illustrating neurochemical abnormalities (St´eru et al., 1985; 
Castagn´e, et al., 2010; Chatterjee et al., 2011). On the other hand this might also further 
suggest that TST and FST might reflect different pathophysiological mechanisms 
underlying immobility as proposed by Chatterjee et al. (2011).   
Finally, Castagn´e, et al. (2010) described numerous advantages of using TST over 
FST such as no induction of hypothermia and the animals once taken out from the 
experimental set up resume instantly normal spontaneous activity. More importantly, 
treadmill exercise decreased immobility time and increased swimming time, irrespectively 
of drug treatment, when compared to their sedentary controls. These behavioural 
observations clearly demonstrate that physical exercise is endowed with 
antidespair/antidepressant-like properties. This further corroborates our TST data showing 
that treadmill exercise decreased the immobility time spent by METH-intoxicated mice 49 
days post-METH (Pereira et al., 2014, unpublished). These antidepressant-like properties 
are independent of locomotor behaviour activity since treadmill exercise had no effect on 
climbing time from both METH- and Cont- trated mice.  We also evaluated novel 
environment exploration of mice 49 days post-METH injection using the OF test during 5 
minutes.  We demonstrated that METH regimen did not significantly alter the general 
physical motor abilities and level of interest in the novelty of the environment as gauged 
by similar total distance travelled, average speed and number of rearings compared to 
saline-treated animals, in the sedentary group. Interestingly, Timár et al. (2003) reported a 
decrease of spontaneous locomotor activity in rats 3 days after METH treatment (10 
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mg/kg, 4 subcutaneous injections every 2 hours). However, this effect was transient since 
1, 2 and 4 weeks after METH administration, animals revealed a normal locomotor 
behavior. This further suggests that the anhedonic-like behavior showed by METH-
intoxicated mice is independent of locomotor activity. However, chronic exercise increased 
all the measured OF parameters in both METH and Cont, suggesting that treadmill 
enhanced both locomotor activity and exploratory behavior. These results could be related 
with the high-mood state triggered by physical exercise as shown by both Splash and FST, 
irrespectively of drug treatment. Consistently, these mice exhibited an anxiolytic-like 
behaviour as gauged by increased center distance–total distance ratio compared to 
sedentary mice.  
Articulating the three behavioral tests used herein, one can propose that treadmill 
exercise offers an antidepressant-like effect to mice submitted to a neurotoxic METH dose. 
This pre-clinical approach gives further credence for the reported benefitial effects of 
physical exercise to METH-abstinent individuals (Mooney et al., 2014). 
We hypothesized that this beneficial impact of treadmill exercise is dependent upon 
its modulatory impact on 5-HT homeostasis in both hippocampus and frontal cortex from 
METH-intoxicated mice. Although METH imposed a robust hippocampal 5-HT depletion 
(circa 45%) at 3 days post-injection, this neurochemical detrimental effect was reversed 49 
days post-injection. On the other hand, treadmill exercise failed to significantly change 5-
HT levels in both saline and METH groups. Importantly, this means that physical exercise 
had no effect on 5-HT hippocampal terminal recovery in METH-intoxicated mice. 
Additionally, frontal cortical 5-HT levels from METH sedentary-intoxicated mice were not 
statistically different from their control saline mice. On the other and, Silva et al. (2014) 
showed that, METH imposed a 5-HT depletion of circa 25% in frontal cortex. Although 
apparently contradictory, these results stress that the 5-HT depletion on frontal cortex was 
not robust enough to be reproducible. One can also add that this METH regimen is more 
detrimental to dopaminergic systems compared to serotonergic systems (Pereira et al., 
2012; Silva et al., 2014). Consistently with hippocampal 5-HT data, treadmill exercise 
failed to significantly change 5-HT levels in frontal cortex from both saline and METH 
groups. Overall, one can discard the hypothesis that treadmill exercise exerted an 
antidepressant-like effect through modulating 5-HT synthesis in both of hippocampal and 
frontal-cortex. However, one cannot disregard the hypothesis that METH-intoxicated mice 
had changes in 5-HT extracellular basal levels and signaling. This warrants further 
scrutiny.   
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Disruption in the neurotrophic factors, which play a major role role in 
neuroplasticity, could be also held responsible for the depressive-like behavior METH-
induced (Matta et al., 2013). Interestingly, it was also postulated that a reduction of 
neurotrophic factors in limbic structures, including the hippocampus and prefrontal cortex 
is directly involved in the pathophysiology of depressive disorders (Duman & Monteggia, 
2006). Therefore, antidepressants might mediate their therapeutic benefit, in part, by 
increasing levels of these factors in the hippocampus.  
Importantly, it was shown that serum brain-derived neurotrophic factor (BDNF) 
levels were significantly downregulated in METH abusers during the first 3 weeks of 
withdrawal (Chen et al., 2012). Another study found that chronic METH abusers who had 
been abstinent for at least 1 month had significantly higher plasma BDNF levels compared 
to healthy control subjects (Kim et al., 2005).  
Taken together, these studies strongly suggest that BDNF, was shown to be 
decreased first and then increased after METH withdrawal in humans. These findings are 
compatible with findings from animal studies. For example, neurotoxic-METH treatment 
in rat increased BDNF in multiple brain regions from rat including frontal cortex and 
hippocampal CA1 (Braun et al., 2011). Therefore probing the role of BDNF in the 
beneficial treadmill exercise in METH-intoxicated mice is warranted.  
On the other hand, there is also substantial evidence showing that regular physical 
exercise is associated with a low reactivity of the sympathetic nervous system (SNS) and 
the HPA axis, that plays a critical role in developing responses to psychological and 
physical stressors (Stranahan et al., 2008 and Rimmele et al., 2009). Specifically, 
physically active subjects showed lower cortisol increase (Rimmele et al., 2007), to 
psychological laboratory stressors in comparison with less active controls. Thus, exercise-
induced changes in HPA axis might modulate negative affects in humans. Importantly, 
adolescent METH use is associated with greater psychiatric symptoms and enhanced 
cortisol secretion following a social stressor, particularly in younger female METH users 
(King et al. 2010). Therefore the relevance of the HPA axis to the antidepressive-like effect 
of treadmill exercise also warrants further analysis. Additionally other brain regions 
including amygdala should be scrutinized. 
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Conclusion 
This study is relevant because it further demonstrated that a single-high METH 
dose imposes a long-lasting depressive-like symptoms such as anhedonia. Furthermore, we 
unequivocally show that physical exercise is a non-pharmacologic strategy that offers 
antidepressive-like effects to METH-intoxicated mice. We also demonstrated that this 
treadmill effect was independent of 5-HT homeostasis in both frontal-cortex and 
hippocampus. Therefore, further studies are warranted to understand the neurochemical 
basis for this positive behavioral effect. 
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